Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study

NCT07390253 is registered in ClinicalTrials.gov with Vienna Institute for Research in Ocular Surgery as lead sponsor.

NCT NCT07390253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07390253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study
Lead sponsor
Vienna Institute for Research in Ocular Surgery
Phase
Observational
Overall status
Active, not recruiting
Start date
September 18, 2024
Completion date
June 1, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration